-- BlinkLab (ASX:BB1) generated a gross AU$17.5 million from an oversubscribed share placement at a price of AU$0.65 per ordinary share, according to a Thursday filing with the Australian bourse.
Members of the company's board and management participated in the placement with a commitment to contribute AU$200,000.
The healthcare company will use the funds to complete a US registrational trial for autism diagnosis using its Dx1 platform while also supporting the lead product's approval processes in Europe.
Additionally, BlinkLab plans launch a second clinical program in the US using its Dx2 platform as a diagnostic aid for attention-deficit/hyperactivity disorder, or ADHD.
Shares of the company were down 3% in recent Thursday trade.